BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 29299828)

  • 1. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
    Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
    Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer.
    Starska K; Forma E; Jóźwiak P; Lewy-Trenda I; Danilewicz M; Stasikowska-Kanicka O; Skóra M; Kolary K; Miazga J; Krześlak A; Bryś M
    Tumour Biol; 2016 Oct; 37(10):13185-13203. PubMed ID: 27456359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma.
    Kim EK; Cho YA; Koh YW; Shin HA; Cho BC; Yoon SO
    BMC Cancer; 2020 Apr; 20(1):348. PubMed ID: 32326908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
    Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
    World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
    Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
    Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
    Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
    BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF-2 Attenuates Neuronal Apoptosis via FGFR3/PI3k/Akt Signaling Pathway After Subarachnoid Hemorrhage.
    Okada T; Enkhjargal B; Travis ZD; Ocak U; Tang J; Suzuki H; Zhang JH
    Mol Neurobiol; 2019 Dec; 56(12):8203-8219. PubMed ID: 31203572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
    Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
    J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
    Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
    Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer.
    Tanaka T; Terai Y; Kogata Y; Ashihara K; Maeda K; Fujiwara S; Yoo S; Tanaka Y; Tsunetoh S; Sasaki H; Kanemura M; Tanabe A; Ohmichi M
    Oncol Rep; 2015 Nov; 34(5):2282-8. PubMed ID: 26351781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.
    Lim S; Koh MJ; Jeong HJ; Cho NH; Choi YD; Cho do Y; Lee HY; Rha SY
    Yonsei Med J; 2016 Jul; 57(4):831-9. PubMed ID: 27189274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
    Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
    Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
    Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
    Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.
    Starska K; Forma E; Jóźwiak P; Bryś M; Lewy-Trenda I; Brzezińska-Błaszczyk E; Krześlak A
    Tumour Biol; 2015 Apr; 36(4):2309-21. PubMed ID: 25412955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.
    Blanca Pedregosa AM; Sánchez-González Á; Carrasco Valiente J; Ruiz García JM; Gómez Gómez E; López Beltrán A; Requena Tapia MJ
    Actas Urol Esp; 2017 Apr; 41(3):172-180. PubMed ID: 27726892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
    Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
    Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
    Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
    Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.